The Hugo™ RAS system has won a “Medical Device Innovation Award” in the 2022 MedTech Breakthrough Awards program.

“After more than 20 years of availability, robotic-assisted surgery only accounts for about 3% of all surgeries performed globally today — despite its potential for fewer complications, shorter hospital stays, and faster recovery,” said James Johnson, managing director, MedTech Breakthrough. “The Hugo™ RAS system from Medtronic is a solution to historic cost and utilization barriers, with key design principles that offer surgeons and hospitals flexibility, redefining what is possible in RAS for practitioners and patients alike.’”

The Hugo™ RAS system is a modular, multi-quadrant platform designed for a broad range of soft-tissue procedures. It combines wristed instruments, 3D visualization, and Touch Surgery™ Enterprise, a cloud-based surgical video capture and management solution, with dedicated support teams specializing in robotics program optimization, service, and training.

The Hugo™ RAS system made its clinical debut in June 2021, in Chile. It has since received CE Mark approval and Health Canada license for urologic and gynecologic procedures and been used in hospitals across three regions globally.

MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market.

Now in its sixth year, the mission of the MedTech Breakthrough Awards program is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including telehealth, clinical administration, patient engagement, electronic health records (EHR), virtual care, medical devices, and medical data. This year’s program attracted more than 3,900 nominations from over 15 countries.

The Hugo™ RAS system is commercially available in certain geographies. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability. In the EU, the Hugo™ RAS system is CE marked. In Canada, the Hugo™ RAS system has a medical device licence. The Hugo™ RAS system is approved in Australia. In the U.S., the Hugo™ RAS system is an investigational device not for sale. Touch Surgery™ Enterprise is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition.

For more information, visit medtronic.com/hugo.

For media assets, please visit https://news.medtronic.com/Robotic-Assisted-Surgery-Technologies.

Contacts:
Gary Jeanfaivre                                                                       
Public Relations                                                                       
+1-203-833-2104